SCHEMBL964992

SCHEMBL964992

CC(C)Nc1ccccc1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.50
TDP1 Q9NUW8 3/20 0.50
KMT2A Q03164 3/20 0.50
THRB P10828 2/20 0.50
MEN1 O00255 2/20 0.50
BLM P54132 1/20 0.50
ALDH1A1 P00352 6/20 0.46
TSHR P16473 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
TRIM24 O15164 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
IDO1 P14902 1/20 0.41
HPGD P15428 2/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
RECQL P46063 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7804693 0.98 LMNA (0.48) LMNATDP1KMT2ATHRBMEN1
SCHEMBL28312506 0.83 LMNA (0.46) LMNATDP1KMT2ATHRBMEN1
SCHEMBL6880406 0.81 TDP1 (0.41) LMNATDP1KMT2ATHRBMEN1
SCHEMBL6286925 0.81 TDP1 (0.41) LMNATDP1KMT2ATHRBMEN1
SCHEMBL20628519 0.80 ALDH1A1 (0.45) LMNATDP1KMT2ATHRBMEN1
SCHEMBL1767594 0.79 LMNA (0.44) LMNATDP1KMT2ATHRBMEN1
SCHEMBL1767595 0.79 LMNA (0.44) LMNATDP1KMT2ATHRBMEN1
SCHEMBL7603406 0.79 KMT2A (0.41) LMNATDP1KMT2ATHRBMEN1
SCHEMBL2962223 0.78 TDP1 (0.57) LMNATDP1KMT2ATHRBMEN1
SCHEMBL874034 0.77 TDP1 (0.55) LMNATDP1KMT2ATHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4582903-A Synthesis of unsaturated hydantoins with an inexpensive catalyst STAUFFER CHEMICAL COMPANY (US) 1986-04-15 US claimed
US-4345072-A Process for the production of 5-arylidene hydantoins (B) DEGUSSA AG (DE) 1982-08-17 US claimed
US-9873692-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-01-23 US disclosed
US-20170334901-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-11-23 US disclosed
US-9630960-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-04-25 US disclosed
US-20160376264-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-12-29 US disclosed
US-9402840-B2 Crystalline form of a quinolinone-carboxamide compound THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-08-02 US disclosed
US-9353106-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-05-31 US disclosed
US-20160095849-A1 CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-04-07 US disclosed
US-20150291580-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-10-15 US disclosed
US-9126994-B2 Crystalline form of a quinolinone-carboxamide compound THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-09-08 US disclosed
US-4684735-A Promotion of raney nickel hydrogenation catalyst STAUFFER CHEMICAL COMPANY (US) 1987-08-04 US disclosed
US-4650876-A INCREMENTAL ADDITION TO PREVENT FOAMING, RANEY CATALYST STAUFFER CHEMICAL COMPANY (US) 1987-03-17 US disclosed
EP-0210683-A1 Promotion of raney nickel catalyst STAUFFER CHEMICAL COMPANY (US) 1987-02-04 EP disclosed
US-4613691-A Preparation of amino acids from unsaturated hydantoins STAUFFER CHEMICAL COMPANY (US) 1986-09-23 US disclosed
EP-0187322-A1 Carbostyril compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-07-16 EP disclosed
US-4582903-A Synthesis of unsaturated hydantoins with an inexpensive catalyst STAUFFER CHEMICAL COMPANY (US) 1986-04-15 US disclosed
EP-0177072-A2 Preparation of amino acids from unsaturated hydantoins STAUFFER CHEMICAL COMPANY (US) 1986-04-09 EP disclosed
EP-0082394-A2 A process for the production of aminophthalides and amino benzoic acids STERLING DRUG INC. (US) 1983-06-29 EP disclosed
US-4345072-A Process for the production of 5-arylidene hydantoins (B) DEGUSSA AG (DE) 1982-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160095849-A1 CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND HTR5A, HTR4, HTR2C LMNA 2512/4885TDP1 2252/4885KMT2A 1371/4885
US-20160376264-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A LMNA 3482/4885TDP1 3148/4885KMT2A 1511/4885
US-20150291580-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A LMNA 3482/4885TDP1 3148/4885KMT2A 1511/4885
US-20170334901-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A LMNA 3482/4885TDP1 3148/4885KMT2A 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.